Concepedia

Stephen Hillerman

SH

Statistics

Publications

6

Citations

658

H-Index

6

Active since

2003

Affiliations

Bristol-Myers Squibb (United States)(Current)

Pfizer (United States)

Stephen Hillerman is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and molecular oncology.

Publications per year

2003–2021

6

Publications

6

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

Joan M. Carboni, Mark D. Wittman, Zheng Yang et al. · Molecular Cancer Therapeutics · 2009 · 281 citations · Full text

Medicine, Cancer Biology, Medicinal Chemistry +16

Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma Model

Fei Huang, Warren Hurlburt, Ann Greer et al. · Cancer Research · 2010 · 116 citations · Full text

Medicine, Oncology, Pharmacology +13

Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity

Michael J. Munchhof, Jean S. Beebe, Jeffery M. Casavant et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 96 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

Dan You, Stephen Hillerman, Gregory Locke et al. · Journal for ImmunoTherapy of Cancer · 2021 · 76 citations · Full text

Medicine, Immunology, Pharmacology +17

Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance

Jinqi Liu, Joshua C. Curtin, Dan You et al. · PLoS ONE · 2019 · 59 citations · Full text

Medicine, Immunology, Oncology +17

1–5 of 6